ArticleJournal of functional biomaterials2026
Engineering Cobalt Bis(dicarbollide)-Loaded Polymeric Nanocarriers: From Controlled Fabrication to Drug Delivery for BNCT.
Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly(lactic-co-glycolic) acid nanoparticles (NPs) with the addition of the sodium salt of cobalt bis(1,2-dicarbollide) (COSAN) were developed for boron neutron capture therapy (BNCT). The Box-Behnken design was applied to predict an optimal value of variables and to obtain the desired NP characteristics. The optimized NPs had a size of 166 nm and a COSAN loading of 16%. Based on FTIR and UV-VIS spectrophotometry data, it was found that COSAN maintains chemical stability during the encapsulation process and exhibits prolonged release from NPs. A study of in vitro cytotoxicity and accumulation of the NPs on B16 cells revealed their low toxicity and high accumulation in cells after 24 h. In vivo analysis in B16-bearing BALB/c nude mice showed preliminary tumor-associated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.